StockData
First Tracks Biotherapeutics, Inc. logo

First Tracks Biotherapeutics, Inc. (TRAX) stock

TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$43.57−2.99 (-6.42%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

First Tracks Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$32.84M–
Q2 FY2026Jun 30, 2026-$34.94M–
Q1 FY2026Mar 31, 2026-$52.81M–
Q3 FY2025Sep 30, 2025-$45.06M–
Q2 FY2025Jun 30, 2025-$45.90M–
Q1 FY2025Mar 31, 2025-$51.28M–

More First Tracks Biotherapeutics figures

See a number that looks wrong?